Nanxin Pharmaceutical: Stocks will be subject to other risk warning measures due to violations of disclosure regulations.

Nanxin Pharmaceuticals announced that on June 9, 2026, it received a "Notice of Administrative Penalty in Advance" from the Hunan Regulatory Bureau of the China Securities Regulatory Commission. In 2023, the company's controlling subsidiary did not offset the income and profits in the current period after returning goods and cash discounts under agreements, resulting in an overstatement of revenue by 64.6828 million yuan and total profit by 11.9522 million yuan in the 2023 annual report. The company, along with Zhang Shixi, Li Liang, and Hu Xinbao, are proposed to be fined 5 million yuan, 2.5 million yuan, 2 million yuan, and 2 million yuan respectively. The Shanghai Stock Exchange will implement other risk warnings for the company's stock, without triggering the circumstances of mandatory delisting due to major violations.